Profile

Business Description

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse®, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse® IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse® IL-12 is currently in Phase II development for several indications, including metastatic melanoma and triple negative breast cancer. In addition to ImmunoPulse® IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

Company Info

Address:
5820 Nancy Ridge Drive
San Diego, CA 92121 US

Telephone:
855-662-6732

Fax:
858-430-3832

Email:
investors@OncoSec.com

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
In-Vitro Diagnostic Substance Manufacturing (325413)

SIC:
Pharmaceutical Preparations (2834)